Journal article icon

Journal article

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status

Abstract:

Overexpression of HER2 is an important prognostic marker, and the only predictive biomarker of response to HER2-targeted therapies in invasive breast cancer. HER2- HER3 dimer has been shown to drive proliferation and tumor progression, and targeting of this dimer with pertuzumab alongside chemotherapy and trastuzumab, has shown significant clinical utility. The purpose of this study was to accurately quantify HER2-HER3 dimerisation in formalin fixed paraffin embedded (FFPE) breast cancer tiss...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.18632/oncotarget.9963

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology, CRUK/MRC Ox Inst for Radiation Oncology
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology, CRUK/MRC Ox Inst for Radiation Oncology
Expand authors...
More from this funder
Grant:
C1519/A6906; C5255/A15935
King’s College London-UCL Comprehensive Cancer Imaging Centre More from this funder
More from this funder
Grant:
KCL Unit Funding KCL 06/07
Expand funders...
Publisher:
Impact Journals Publisher's website
Journal:
Oncotarget Journal website
Publication date:
2016-07-07
DOI:
ISSN:
1949-2553
URN:
uuid:85852ba8-676c-4e8f-b167-6269689247bd
Source identifiers:
623824
Local pid:
pubs:623824

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP